Thoughts on biotech and pharmaceutical stocks from Bio5C founder, JNap.
Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Decent at golf.
Healthcare lies at the confluence of science, clinical practice, and regulation. I analyze trends, data, and diseases with eye toward biotech and a touch of humor
Weekly posts on small and mid-cap biotech stocks. 100% independent and reader supported with no company sponsored content or hedge fund compensation of any kind. See free performance posts for more information. Not financial advice, for research purposes.
+20.43% CAGR since 2018. Real-money small-cap research balancing long-term compounders with catalyst-driven multibaggers. Full track record and historical case studies on the About page.